Standard BioTools
LAB
143 hedge funds and large institutions have $244M invested in Standard BioTools in 2026 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 51 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
0.35% less ownership
Funds ownership: 76.2% → 75.86% (-0.35%)
8% less funds holding
Funds holding: 156 → 143 (-13)
11% less capital invested
Capital invested by funds: $273M → $244M (-$29.8M)
18% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 51
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
55% less call options, than puts
Call options by funds: $26K | Put options by funds: $58K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$7.07M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.89M |
| 3 |
MCO
MAK Capital One
New York
|
+$2.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.47M |
| 5 |
Jane Street
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$15.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.74M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.21M |
| 4 |
Barclays
London,
United Kingdom
|
-$2.43M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$1.62M |
LAB Hedge Fund Activity: Q2 2026 in Review
143 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2026, worth a combined $244M — down 11% from $273M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of LAB and 42 opened new positions — a net loss of 9 holders — while 36 trimmed existing stakes and 47 added.
The largest buyer was Long Focus Capital Management, adding an estimated $7.07M. The largest seller was BlackRock, cutting an estimated $15.6M.
- 143 institutional investors held Standard BioTools (LAB) as of Q2 2026, down from 156 in Q1 2026.
- Funds reported $244M of Standard BioTools stock for Q2 2026, down 11% quarter-over-quarter.
- 42 funds opened new Standard BioTools positions in Q2 2026 and 51 closed out, a net change of -9 holders.
- The largest Standard BioTools buyer in Q2 2026 was Long Focus Capital Management, an estimated $7.07M added.
- The largest Standard BioTools seller in Q2 2026 was BlackRock, an estimated $15.6M sold.
Based on aggregated 13F filings for Q2 2026.